Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TXN10128 in advanced solid tumors
NCT05978492Phase 1Recruiting
- Sponsor
- Txinno Bioscience
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TXN10128 in solid tumor (3 arms), sponsored by Txinno Bioscience. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events. Started Jul 2023; status: recruiting.
02
Drugs
TXN10128
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05978492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05978492.